About Dr. Sweeney's Lab

Our multidisciplinary research program spans molecular and cellular analyses, integrative physiology approaches for preclinical phenotyping, clinical and drug discovery studies. It is focused on obesity, diabetes & heart failure (cardiometabolic disease: CMD), particularly with a focus on adiponectin, and designed to:
a) implement & conduct innovative basic research to uncover novel mechanisms of CMD.
b) identify & develop transformative strategies for discovering
i) innovative biomarkers which confer early & accurate risk prediction;
ii) novel, effective & safe therapeutic intervention.

Our Team

Dr Sweeney has given invited presentations at annual conferences of Heart Failure Society of America, European Association for Study of Diabetes, International Society for Heart Research, Society for Heart & Vascular Metabolism, American College Cardiology and national or international academic institutions. Trainees have an outstanding recognition track record: eg. Euro Congress of Endocrinology abstract & oral presentation judged one of 4 prize winners from >1000 abstracts; Mitacs Globalink Awards; Best Young Investigator Award Society Heart Vascular Metabolism; CIHR, Canadian Diabetes Association plus Heart & Stroke Foundation Fellowships & Studentships. Dr Sweeney is regularly invited to serve on peer review panels: eg. CIHR committee member and CIHR committee Scientific Officer, Canadian Diabetes Association grant review and personnel committees, Heart & Stroke Foundation grant review committee, and as Chair of FRSQ review committee. He has served as Consulting Editor for Diabetes, Editorial Board Member of American Journal of Physiology (Endocrinology & Metabolism) and as Associate Editor of Frontiers in Cellular Endocrinology as well as several other editorial appointments.​

Funding

Canadian Institutes for Health Research
Project grants

Thalassemia Foundation of Canada
grant

International Development Research Council
Team grant (Israel & Thailand)

Heart & Stroke Foundation of Canada
Grant

Allysta Pharmaceuticals Inc.
Research contract

Thalassemia Foundation of Canada / Mitacs
Research grant